If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
203
results.
Updated on
19/04/2025 [06:52:00]
Absstract of: CN119841848A
本发明公开了一种新型AIE光热剂及其制备方法与应用。本发明的AIE光热剂的结构式如下所示，其发光性能和光热转化性能优越，可用于制备肿瘤诊断试剂或肿瘤治疗药物。本发明制备的负载AIE光热剂和STING激动剂的仿生纳米粒子能够实现药物至肿瘤组织高效递送，基于AIE分子的多模态成像能力对肿瘤进行靶向示踪，其光热效应能够增强肿瘤细胞ICD和DC细胞的STING通路激活，增增强抗肿瘤免疫治疗，最终抑制远端肿瘤生长，肿瘤复发和再转移。本发明材料制备工艺简单，成本较低，适用于规模生产和临床医疗使用。#imgabs0#
Absstract of: CN119837842A
本发明提供一种基于超氧化物歧化酶的纳米透皮递送系统，为小分子活性成分‑超氧化物歧化酶‑聚合物壳层的胶囊复合结构，小分子活性成分负载在超氧化物歧化酶中，超氧化物歧化酶表面被聚合物壳层包覆，所述基于超氧化物歧化酶的活性成分透皮递送系统直径为20‑100nm，聚合物壳层厚度为7.5‑52.5nm。本发明递送系统中聚合物壳层为超氧化物歧化酶和具有抗氧化作用的小分子功能物质提供保护作用，所述胶囊复合结构为纳米凝胶的形式，纳米凝胶不仅促进其渗透深度，而且减轻了其对皮肤的刺激作用。本发明原料生物友好，制备方法简单，收率高，可以工业化大规模生产。
Absstract of: CN119841930A
本发明公开了一种抗原MNA及其应用和制备的疫苗、药物，属于生物医药技术领域。本发明发现并设计的新型肿瘤新抗原（MNA）具有强免疫原性，能够有效激活T细胞免疫反应；且仅在肿瘤细胞中表达，不受中枢免疫耐受的影响，能够精准靶向肿瘤细胞，减少对正常组织的损伤。且利用circRNA作为新抗原MNA的表达载体，稳定性高，高效表达，诱导强烈的新抗原特异性T细胞反应，无需佐剂。本发明为肿瘤新抗原疫苗的开发和个性化免疫治疗提供了新的思路，有助于推广至更多的高突变负荷肿瘤类型，具有广阔的临床应用前景。
Absstract of: TW202412846A
The present invention addresses the problem of providing a novel copolymer that can be used for a drug delivery technique. The present invention relates to a copolymer obtained by binding a target-affinity molecule to a copolymer X comprising structural units represented by formula (A), (B), and (C). In the formulae, R1, R2, and R3 are the same or different and each represent a hydrogen atom or a C1-3 alkyl group; R4 represents a C1-3 alkyl group; R5 represents a hydrogen atom, a C1-18 alkyl group, an optionally substituted, 3- to 8-membered cycloalkyl group, an adamantyl group, an optionally substituted C6-18 aryl group, or an optionally substituted, 5- to 10-membered heteroaryl group; X1, X2, and X3 are the same or different and each represent an oxygen atom, a sulfur atom, or N-R7; R6 represents a hydrogen atom, a leaving group, or a linker; R7 represents a hydrogen atom or a C1-3 alkyl group; m is an integer of 1-100; and n is an integer of 0-3..
Absstract of: CN119838009A
本发明公开了一种肿瘤免疫微环境调控型光激活铁死亡纳米粒及其制备方法和应用，涉及生物医药技术领域。该制备方法包括以下步骤：将白蛋白和铁蛋白溶于水中，调节pH为碱性后加入光敏剂和硫辛酸，混合后再加入溶剂，进行混合反应，之后加入交联剂，继续反应后，经过离心和干燥处理，得到所述肿瘤免疫微环境调控型光激活铁死亡纳米粒。该肿瘤免疫微环境调控型光激活铁死亡纳米粒通过诱导肿瘤细胞铁死亡、激活树突状细胞和调控M2型肿瘤相关巨噬细胞的M1型极化来逆转肿瘤免疫抑制微环境，进而增强肿瘤免疫治疗效果。
Absstract of: CN119841854A
本发明涉及药物技术领域，具体提供了一种活性氧响应的紫杉醇前药，具有式Ⅰ或式Ⅱ所示结构。本发明针对紫杉醇疏水聚集问题，对紫杉醇药物进行了改性，改性后的紫杉醇药物水溶性大大增强，并获得了自组装性能，在水溶液中可以进行自组装得到纳米粒子，所述纳米粒子具有超高的载药量和载药效率，并且可以特异性响应肿瘤微环境中高浓度的活性氧，既能改善传统紫杉醇纳米制剂载药量的不足，又能在肿瘤位置响应释放紫杉醇，有利于减少药物用量，降低毒副作用，对提升患者预后，延长患者生存期具有重要意义。
Absstract of: CN119837843A
本发明属于生物医药技术领域，公开一种用于治疗阿尔兹海默症的双药纳米颗粒及其制备方法和应用，将Aβ抑制剂通过化学键连接在两亲性聚合物上，连有Aβ抑制剂的两亲性聚合物和STING抑制剂混合，在超声下缓慢的滴加到水中，超声、过滤取上层，得到双药纳米颗粒，本发明制备的双药纳米颗粒具有较好的生物相容性、稳定性，能穿过血脑屏障并同时对Aβ和小胶质细胞STING通路作用，解聚Aβ并促进Aβ清除、抑制小胶质细胞STING通路激活，减少释放炎症因子损伤神经元；能明显减少脑部沉积的Aβ和显著抑制脑内小胶质细胞STING通路的激活，明显的改善了小鼠记忆能力、空间识别能力，改善了脑部炎性微环境。
Absstract of: CN119837841A
本发明提供一种用于皮肤抗炎的蓝萼甲素纳米透皮递送系统，为蛋白‑蓝萼甲素‑聚合物壳层的胶囊复合结构，所述蛋白对皮肤有亲和作用，蓝萼甲素负载于蛋白中，聚合物层包覆在蛋白的表面，所述蓝萼甲素纳米透皮递送系统尺寸为30‑80nm，聚合物壳层厚度为10‑35nm。聚合物外壳表面性质可以根据透皮递送的深度需求进行调控，使得蛋白质突破皮肤屏障被高效递送至皮肤深处再将蓝萼甲素缓慢释放，靶向缓解皮肤炎症，解决蓝萼甲素治疗皮肤炎症因透皮效果不理想而治疗效果低下的缺陷。
Absstract of: US2025120912A1
Synergistic nanomedicine delivering topoisomerase I toxin (SN-38) and inhibitors of polynucleotide kinase 3′-phosphatase (PNKP) for enhanced treatment of colorectal cancer
Absstract of: US2025120928A1
The present disclosure provides polymer-drug conjugates comprising suberoylanilide hydroxamic acid (SAHA), derivatives thereof, and salts thereof. The disclosure further provides nanoparticles comprising the polymer-drug conjugate. The disclosure provides methods of treating a disease or disorder in a subject by administering the conjugate or a plurality of nanoparticles comprising the conjugate to the subject. In some embodiments, the disease or disorder is sepsis, septic shock, hemorrhagic shock, or poly-trauma.
Absstract of: US2025121079A1
This disclosure relates to targeted protease compositions and uses related thereto. In certain embodiments, the disclosure relates to nanoparticles wherein a targeting molecule is linked to the nanoparticle and wherein a catalytic domain of a protease is linked to the nanoparticle. In certain embodiments, the targeting molecule and the catalytic domain are within a single polypeptide sequence. In certain embodiments, the targeting molecule binds a molecule more highly expressed on cancer cells then non-cancerous cells, and the nanoparticles disclosed herein are used for the treatment of cancer by further attaching an anti-cancer agent to the nanoparticle or incorporating an anticancer agent within the nanoparticle.
Absstract of: US2025121043A1
The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.
Absstract of: AU2023357320A1
The present disclosure provides RNA technologies for targeting Claudin-18.2 polypeptides. In some embodiments, such RNA technologies can be useful for treatment of diseases associated with positive expression of Claudin-18.2. For example, in some embodiments, such RNA technologies can be useful for treatment of Claudin-18.2 positive cancer, including, e.g., but not limited to biliary cancers, ovarian cancers, gastric cancers, gastro-esophageal cancers, pancreatic cancers. In some embodiments, such RNA technologies can be used in combination therapy (e.g., in combination with a chemotherapeutic agent). The present disclosure further provides RNA backbones containing specific sequences upstream and/or downstream from the coding sequence.
Absstract of: US2025120914A1
The present disclosure relates to lipid nanoparticles and methods of delivering active agents to target organs, tissues, or cells by utilizing the lipid nanoparticles.
Absstract of: US2025120913A1
A pharmaceutical composition of Quercetin nanosuspension comprising Quercetin dihydrate, about 0.1% w/w to 10% w/w of Poloxamer, about 0.1% w/w to 10% w/w of polyvinyl pyrrolidone, and about 0.1% w/w to 10% w/w of polyethylene glycol. A method for preparing Quercetin nanosuspension, comprising the steps of dissolving polyvinyl pyrrolidone, Poloxamer, and polyethylene glycol in purified water, adding Quercetin to the above solution, subjecting the resulting mixture to bead milling to form Quercetin nanocrystals or nanosuspension.
Absstract of: US2025122247A1
The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
Absstract of: US2025121052A1
Disclosed herein are vaccine compositions that include SARS-CoV-2 MHC epitope-encoding cassettes and/or full-length SARS-CoV-2 proteins. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.
Absstract of: US2025121098A1
The present invention provides nanoparticles or conjugates comprising at least one ligand that selectively targets major facilitator superfamily domain-containing protein-2a (MFSD2A). In various embodiments, the nanoparticles or conjugates of the invention target at least one cell comprising MFSD2A (e.g., endothelial cells of blood brain barrier). In some embodiments, the nanoparticles or conjugates of the invention cross the blood brain barrier and/or blood retinal barrier. In other aspects, the present invention relates to methods for in vivo delivery of diagnostic and/or therapeutic agents to a brain. In other aspects, the present invention relates to methods of preventing or treating a neurological or cognitive disease or disorder using the nanoparticles or conjugates of the invention.
Absstract of: US2025120997A1
Disclosed herein is a composition including a nucleoside-modified mRNA encapsulated in a lipid nanoparticle wherein the nucleoside-modified mRNA encodes IL10, IL-6, MIP1a, GDNF (glial cell line-derived neurotrophic factor), or a combination thereof. A method of treated spinal cord injury is also described.
Absstract of: US2025120916A1
The instant disclosure teaches a highly efficient cellulose-based nanoadsorbent that can capture more than 6000 mg of doxorubicin (DOX), one of the most widely used chemotherapy drugs, per gram of the adsorbent at physiological conditions. Such drug capture capacity is more than 3200% higher than other nanoadsorbents, such as DNA-based platforms. The disclosure teaches how anionic hairy cellulose nanocrystals, also known as electrosterically stabilized nanocrystalline cellulose (ENCC), bind to positively charged drugs in human serum and capture DOX immediately without imposing any cytotoxicity and hemolytic effects. The disclosure further elucidates how ENCC provides a remarkable platform for biodetoxification at varying pH, ionic strength, ion type, and protein concentration. These discoveries pave the way for the next generation in vitro and in vivo drug capture additives and devices.
Absstract of: US2025120904A1
A method and apparatus for the targeted delivery of chemotherapy to a surgical cavity, consisting of a triggered nanoparticle encapsulating a therapeutic agent and an energy delivery device that applied trigger energy to the surgical cavity. Following surgical removal of a cancerous tumor, the nanoparticle is administered, and the energy delivery device applies trigger energy to the surgical cavity and proximal tissue. The goal is the delivery of a therapeutic drug dose to cancerous and precancerous cells remaining after surgery, to prevent local tumor recurrence.
Absstract of: WO2023238137A1
One or more ionizable lipid(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided.
Absstract of: EP4537813A1
The present invention relates to: a thermo-sensitive poly(organophosphazene) polymer loaded with a drug; a pharmaceutical composition for preventing or treating inflammatory diseases, comprising same; and the like. An injectable polymer nanoparticle hydrogel system comprising the hydrogel has a long-term anti-inflammatory effect and can slowly release a drug at a therapeutically-effective concentration, and thus can be used in the prevention and treatment of various inflammatory diseases such as osteoarthritis.
Absstract of: WO2023239593A1
The invention relates to a method of treating a disease or disorder in a patient in need thereof that includes providing an active pharmaceutical ingredient (API) to the patient by administering more than one split-dose of the API over a pre-determined period of time. In embodiments of the invention, the API is an mRNA encoding an antigen. The attractiveness of mRNA as a vaccine modality is supported by several advantages. As a non-infectious agent that does not require incorporation into the host's genome to confer activity along with its well-defined chemical composition, mRNA is regarded as a relatively safe vaccine modality.
Nº publicación: EP4536625A1 16/04/2025
Applicant:
ACADEMIA SINICA [TW]
Academia Sinica
Absstract of: CN119173498A
The present disclosure relates to novel lipids, nanoparticles comprising such lipids and their use for delivering therapeutic agents to a subject or treating and/or preventing a disease in the subject.
BOPI
Electronic site
